PV-10 Chemoablation of Recurrent Breast Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-10-31

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the treatment of recurrent breast carcinoma. This study will also include a preliminary assessment of response of injected lesions by histologic assessment upon lesion excision at 1-3 weeks following IL PV-10 administration. Post-excision wound healing will be assessed clinically at 1 week and 4 weeks following excision of PV-10 injected lesions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single center, open label, ascending dose study. Subjects with at least one recurrent, histologically confirmed measurable soft tissue breast carcinoma who are candidates for lumpectomy (removal of the lesion from the site of recurrence in the breast or at another site) or mastectomy will receive a single intralesional injection of PV-10 into a single target lesion to uniformly infiltrate the target lesion and up to a 0.5 cm margin at a dose of up to 1.0 mL/cc lesion volume. Systemic and locoregional adverse events will be monitored over the study interval. Subject accrual and PV-10 administration will be stopped if more than 1 subject has a treatment related Grade 3 non-hematological or Grade 4 hematological toxicity within a period of two weeks after PV-10 administration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Recurrent soft tissue breast carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PV-10 (rose bengal disodium 10%)

PV-10 ablation of study lesion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Biopsy confirmed recurrent soft tissue breast carcinoma
* At least one measurable target lesion at least 0.5 cm and no more than 3 cm in longest diameter
* Performance Status: Karnofsky 70-100% or ECOG 0-2
* Life Expectancy: At least 6 months
* Hematopoietic:

* White blood cell count (WBC) at least 3000/mm3
* Absolute neutrophil count (ANC) at least 1.5 (1,500/mm3)
* Hemoglobin at least 10 g/dL
* Platelet count at least 100,000/mm3
* Coagulopathy: International Normalized Ratio (INR) at least 1.5.
* Renal Function: Creatinine = 0.05-0.11 mmol/L
* Hepatic Function:

* Bilirubin = 3-21 umol/L
* AST/ALT ≤ 3 times the upper limit of normal (ULN)
* Cardiovascular Function: No major cardiovascular disease
* Thyroid Function: T3 (serum triiodothyronine), T4 (serum thyroxine) and THS (serum thyrotropin) within normal limits
* Immunological Function: Adequate immune system function in the opinion of the investigator

Exclusion Criteria

* Radiation therapy to study lesions within 4 weeks
* Chemotherapy or other systemic cancer therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin)
* Local treatment (e.g., surgery, cryotherapy, radiofrequency ablation) to the treatment area within 4 weeks
* Investigational agents within 4 weeks (or 5 half-lives)
* Anti-tumor vaccine therapy within 12 weeks
* Concurrent illness:

* Severe diabetes or extremity complications due to diabetes
* Significant concurrent disease or illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the investigator, compromise subject safety or compliance or interfere with interpretation of study results
* Thyroid autoregulatory dysfunction, including thyroid disease (subclinical or ongoing), goiter, partial thyroidectomy, prior radioiodine- or surgically-treated Graves' hyperthyroidism, or cystic fibrosis
* Pregnancy or fertile female subjects who are not using effective contraception, or who are lactating
* Known or suspected brain metastases or spinal cord compression.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Provectus Pharmaceuticals, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eric Wachter, Ph.D.

Role: STUDY_DIRECTOR

Provectus Pharmaceuticals, Inc.

Chris Wynne, M.D.

Role: PRINCIPAL_INVESTIGATOR

Oncology Service, Christchurch Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Canterbury BreastCare

Christchurch, , New Zealand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

New Zealand

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PV-10-BC-04

Identifier Type: -

Identifier Source: org_study_id